{"id":913587,"date":"2025-11-25T08:50:03","date_gmt":"2025-11-25T13:50:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\/"},"modified":"2025-11-25T08:50:03","modified_gmt":"2025-11-25T13:50:03","slug":"halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\/","title":{"rendered":"Halozyme to Participate in the 8th Annual Evercore Healthcare Conference"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">SAN DIEGO<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Nov. 25, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0Halozyme Therapeutics, Inc. (NASDAQ: HALO) (&#8220;Halozyme&#8221;) today announced that Dr. <span class=\"xn-person\">Helen Torley<\/span>, president and chief executive officer, will present and host investor meetings at the 8th Annual Evercore Healthcare Conference.<\/p>\n<p>The presentation is scheduled for <span class=\"xn-chron\">Tuesday, December 2<\/span> at <span class=\"xn-chron\">10:20am PT<\/span> \/ <span class=\"xn-chron\">1:20pm ET<\/span>.<\/p>\n<p>A live audio webcast will be available on the\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4566124-1&amp;h=1267889831&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3560146-1%26h%3D61534635%26u%3Dhttps%253A%252F%252Fir.halozyme.com%252Foverview%252Fdefault.aspx%26a%3DInvestor%2BRelations%2Bsection&amp;a=Investor+Relations+section\" target=\"_blank\" rel=\"nofollow\">Investor Relations section<\/a>\u00a0of the Company&#8217;s website. Replays of the audio webcasts will be available for 90 days following the conference.<\/p>\n<p>\n        <b>About Halozyme<\/b>\n      <\/p>\n<p>Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies.<\/p>\n<p>As the innovators of ENHANZE\u00ae drug delivery technology with the proprietary enzyme rHuPH20, Halozyme&#8217;s commercially validated solution facilitates the subcutaneous delivery of injected drugs and fluids, reducing treatment burden and improving convenience. ENHANZE\u00ae has touched more than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, and Merus N.V.<\/p>\n<p>Halozyme is also developing Hypercon\u2122 to expand the breadth of its drug delivery technology portfolio. Hypercon\u2122 is an innovative microparticle technology that is expected to set a new standard in hyper concentration of drugs and biologics that can reduce the injection volume for the same dosage and expands opportunities for at-home and health care provider administration. The addition of Hypercon\u2122 enhances our ability to transform the patient treatment experience by enabling the creation and delivery of highly concentrated biologics, substantially broadening the scope of therapeutics that can be delivered subcutaneously. The Hypercon\u2122 technology has been licensed to leading biopharmaceutical partners, including Johnson &amp; Johnson, Eli Lilly, and argenx.<\/p>\n<p>Halozyme also develops, manufactures, and commercializes drug-device combination products using advanced auto-injector technologies designed to improve convenience, reliability, and tolerability, enhancing patient comfort and adherence. The Company has two proprietary commercial products, Hylenex\u00ae and XYOSTED\u00ae, partnered commercial products, and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc.<\/p>\n<p>Halozyme is headquartered in <span class=\"xn-location\">San Diego, CA<\/span>, with offices in <span class=\"xn-location\">Ewing, NJ<\/span>; <span class=\"xn-location\">Minnetonka, MN<\/span>; and <span class=\"xn-location\">Boston, MA.<\/span><span class=\"xn-location\">Minnetonka<\/span> is also the site of its operations facility.<\/p>\n<p>For more information, visit <a href=\"http:\/\/www.halozyme.com\" rel=\"nofollow\">www.halozyme.com<\/a> and connect with us on LinkedIn and Twitter.<\/p>\n<p>\n        <b>Contact: <\/b>\n      <\/p>\n<p>Tram Bui<br \/>VP, Investor Relations and Corporate Communications<br \/>609-333-7668\u00a0<br \/><a href=\"mailto:tbui@halozyme.com\" target=\"_blank\" rel=\"nofollow\">tbui@halozyme.com<\/a><\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder3186\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.jpg\" title=\"Halozyme Therapeutics, Inc. Logo. (PRNewsFoto\/Halozyme Therapeutics, Inc.) (PRNewsfoto\/Halozyme Therapeutics, Inc.)\" alt=\"Halozyme Therapeutics, Inc. Logo. (PRNewsFoto\/Halozyme Therapeutics, Inc.) (PRNewsfoto\/Halozyme Therapeutics, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=LA32621&amp;sd=2025-11-25\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference-302625341.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference-302625341.html<\/a><\/p>\n<p>SOURCE  Halozyme Therapeutics, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA32621&amp;Transmission_Id=202511250830PR_NEWS_USPR_____LA32621&amp;DateId=20251125\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SAN DIEGO , Nov. 25, 2025 \/PRNewswire\/ &#8212;\u00a0Halozyme Therapeutics, Inc. (NASDAQ: HALO) (&#8220;Halozyme&#8221;) today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the 8th Annual Evercore Healthcare Conference. The presentation is scheduled for Tuesday, December 2 at 10:20am PT \/ 1:20pm ET. A live audio webcast will be available on the\u00a0Investor Relations section\u00a0of the Company&#8217;s website. Replays of the audio webcasts will be available for 90 days following the conference. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE\u00ae drug delivery technology with the proprietary enzyme rHuPH20, Halozyme&#8217;s commercially validated solution facilitates &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Halozyme to Participate in the 8th Annual Evercore Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-913587","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Halozyme to Participate in the 8th Annual Evercore Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Halozyme to Participate in the 8th Annual Evercore Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO , Nov. 25, 2025 \/PRNewswire\/ &#8212;\u00a0Halozyme Therapeutics, Inc. (NASDAQ: HALO) (&#8220;Halozyme&#8221;) today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the 8th Annual Evercore Healthcare Conference. The presentation is scheduled for Tuesday, December 2 at 10:20am PT \/ 1:20pm ET. A live audio webcast will be available on the\u00a0Investor Relations section\u00a0of the Company&#8217;s website. Replays of the audio webcasts will be available for 90 days following the conference. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE\u00ae drug delivery technology with the proprietary enzyme rHuPH20, Halozyme&#8217;s commercially validated solution facilitates &hellip; Continue reading &quot;Halozyme to Participate in the 8th Annual Evercore Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-25T13:50:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Halozyme to Participate in the 8th Annual Evercore Healthcare Conference\",\"datePublished\":\"2025-11-25T13:50:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\\\/\"},\"wordCount\":422,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/75076\\\/halozyme_therapeutics_logo_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\\\/\",\"name\":\"Halozyme to Participate in the 8th Annual Evercore Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/75076\\\/halozyme_therapeutics_logo_Logo.jpg\",\"datePublished\":\"2025-11-25T13:50:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/75076\\\/halozyme_therapeutics_logo_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/75076\\\/halozyme_therapeutics_logo_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Halozyme to Participate in the 8th Annual Evercore Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Halozyme to Participate in the 8th Annual Evercore Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Halozyme to Participate in the 8th Annual Evercore Healthcare Conference - Market Newsdesk","og_description":"PR Newswire SAN DIEGO , Nov. 25, 2025 \/PRNewswire\/ &#8212;\u00a0Halozyme Therapeutics, Inc. (NASDAQ: HALO) (&#8220;Halozyme&#8221;) today announced that Dr. Helen Torley, president and chief executive officer, will present and host investor meetings at the 8th Annual Evercore Healthcare Conference. The presentation is scheduled for Tuesday, December 2 at 10:20am PT \/ 1:20pm ET. A live audio webcast will be available on the\u00a0Investor Relations section\u00a0of the Company&#8217;s website. Replays of the audio webcasts will be available for 90 days following the conference. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE\u00ae drug delivery technology with the proprietary enzyme rHuPH20, Halozyme&#8217;s commercially validated solution facilitates &hellip; Continue reading \"Halozyme to Participate in the 8th Annual Evercore Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-25T13:50:03+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Halozyme to Participate in the 8th Annual Evercore Healthcare Conference","datePublished":"2025-11-25T13:50:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\/"},"wordCount":422,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\/","name":"Halozyme to Participate in the 8th Annual Evercore Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.jpg","datePublished":"2025-11-25T13:50:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/75076\/halozyme_therapeutics_logo_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/halozyme-to-participate-in-the-8th-annual-evercore-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Halozyme to Participate in the 8th Annual Evercore Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/913587","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=913587"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/913587\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=913587"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=913587"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=913587"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}